Form 4: Telesis Bio Inc. President & COO Eric Esser Reports Stock Transactions

Eric Esser, President & COO of Telesis Bio Inc., reports acquisition of restricted stock units and stock options, as well as shares withheld for tax obligations.

Summary

• On June 22, 2023, Eric Esser, President & COO of Telesis Bio Inc., was granted 32,600 restricted stock units (RSUs) and stock options to purchase 263,600 shares.
• The RSUs vest 25% annually starting March 1, 2024, and the stock options vest 25% on March 1, 2024, with the remainder vesting monthly thereafter.
• On March 1, 2024, 3,340 shares were withheld by Telesis Bio Inc. to cover tax obligations related to the vesting of RSUs at a price of $0.528 per share.
• Following these transactions, Esser directly owns 29,260 shares of common stock and holds options for 263,600 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It is neutral in tone and does not convey any positive or negative sentiment about the company's performance or prospects.

Positives

• The grant of RSUs and stock options to the President & COO aligns his interests with those of the shareholders.
• The vesting schedule of the RSUs and stock options incentivizes continued service and performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the compensation and equity ownership of key executives.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders due to potential dilution from the vesting of RSUs and exercise of stock options.

Key Dates

Keywords

Form 4, Telesis Bio Inc., Eric Esser, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading